Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.52 |
| ▸ | FABP7 | O15540 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TNF | P01375 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31378081 | 1.00 | KMT2A (0.59) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL5497604 | 0.93 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL1853371 | 0.91 | KMT2A (0.64) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL2401694 | 0.89 | KMT2A (0.70) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL5972005 | 0.89 | KMT2A (0.70) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30988970 | 0.88 | KMT2A (0.54) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL7262938 | 0.87 | KMT2A (0.50) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30103837 | 0.87 | KMT2A (0.53) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL3623157 | 0.87 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL31419530 | 0.86 | KMT2A (0.49) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SUPERTRANS MEDICAL LTD (IL) | 2024-02-29 | — | — | US | disclosed |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT INC (US) | 2023-10-05 | — | — | US | disclosed |
| US-11649220-B2 | Probucol derivative, preparation method therefor and use thereof | DEMOTECH.INC. (CN) | 2023-05-16 | — | — | US | disclosed |
| US-20220204565-A1 | Cyclic Peptide Antiviral Agents and Methods Using Same | UNIV DREXEL (US) | 2022-06-30 | — | — | US | disclosed |
| US-20220204565-A1 | Cyclic Peptide Antiviral Agents and Methods Using Same | UNIV DREXEL (US) | 2022-06-30 | — | — | US | disclosed |
| US-20190375792-A1 | Cyclic Peptide Antiviral Agents and Methods Using Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-12-12 | — | — | US | disclosed |
| US-20190375792-A1 | Cyclic Peptide Antiviral Agents and Methods Using Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-12-12 | — | — | US | disclosed |
| US-20180119151-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING DELIVERY FUNCTION AND GENE EXPRESSION REGULATING ABILITY | BONAC CORPORATION (JP) | 2018-05-03 | — | — | US | disclosed |
| WO-2018053013-A1 | CYCLIC PEPTIDE ANTIVIRAL AGENTS AND METHODS USING SAME | DREXEL UNIVERSITY (US) | 2018-03-22 | — | — | WO | disclosed |
| WO-2001029065-A1 | PROCESS FOR PREPARING PEPTIDE INTERMEDIATES | MERCK SHARP & DOHME LIMITED (GB) | 2001-04-26 | — | — | WO | disclosed |
| US-6184389-B1 | FEATURE A PLURALITY OF FUNCTIONAL GROUPS ATTACHED TO BACKBONE AND PHOSPHORAMIDATE SITES | ISIS PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
| EP-0865439-A4 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS INC (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0865439-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1998-09-23 | — | — | EP | disclosed |
| US-5714606-A | OLIGONUCLEOTIDE HAVING RECEPTOR BINDING SITES; ENZYME INHIBITORS, ANTIINFLAMMATORY AGENTS, MEDICAL DIAGNOSIS | ISIS PHARMACEUTICALS, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| EP-0739335-A4 | PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 1997-04-02 | — | — | EP | disclosed |
| WO-1996040672-A1 | COMBINATORIAL LIBRARIES HAVING AMINODIOL MONOMER SUBUNITS | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0739335-A1 | PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 1996-10-30 | — | — | EP | disclosed |
| US-5519134-A | ANTIINFLAMMATORY AGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-21 | — | — | US | disclosed |
| WO-1995018792-A1 | PYRROLIDINE-CONTAINING MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180119151-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE HAVING DELIVERY FUNCTION AND GENE EXPRESSION REGULATING ABILITY | ZFX, ZFR, SRRT | KMT2A 1325/4885FABP5 1834/4885FABP7 1081/4885 |
| US-20190375792-A1 | Cyclic Peptide Antiviral Agents and Methods Using Same | VIP, CCL5, ZC3HAV1 | KMT2A 4728/4885FABP5 3247/4885FABP7 3769/4885 |
| US-11649220-B2 | Probucol derivative, preparation method therefor and use thereof | PNLIP, FAR1, CETP | KMT2A 4090/4885FABP5 259/4885FABP7 67/4885 |
| US-20220204565-A1 | Cyclic Peptide Antiviral Agents and Methods Using Same | ZC3HAV1, VIP, LNPEP | KMT2A 3656/4885FABP5 2507/4885FABP7 3564/4885 |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | TOP2A, TOP1, XPA | KMT2A 2733/4885FABP5 4634/4885FABP7 4808/4885 |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CD47, CLTA, FCGR2A | KMT2A 1155/4885FABP5 362/4885FABP7 1244/4885 |
| US-20240066135-A1 | DRUG CONJUGATES AND USES THEREOF | SLC7A1, ABCB11, SLC1A5 | KMT2A 3532/4885FABP5 1135/4885FABP7 1607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.